Gauri Kamath is a freelance journalist and a keen observer of the pharmaceutical and healthcare sectors. Starting as an intern in the Mumbai newsroom of the Business Standard newspaper in 1998, Gauri has closely followed the pharma and healthcare sectors first as a reporter, then a features writer, and later, a blogger, commentator and content specialist. Her former employers include The Economic Times newspaper and Businessworld magazine. In 2012, she left journalism and worked as a content writer for the pharma and healthcare sectors before going back to journalism in early 2021. During this time,  she also commentated on the sectors through columns published in Indian Express and, among others. Currently, she is Contributing Editor at Shaastra, a science and technology (S&T) magazine published by IIT Madras, where her writing captures developments in drugs, healthcare and medical technology through the prism of S&T.  

Click on the links below to read some of Gauri’s writing

Closer to a cure : The potential of cell and gene therapeutics to provide lasting cures to incurable diseases is attracting a growing number of Indian scientists and companies – Shaastra

Taking root : Indian scientists are turning to medicinal plants for new drugs to treat diseases such as dengue and diabetes – Shaastra

On your biomarkers : From cough sounds to exhaled breath, and from sweat to tears, researchers are peering through new window into the human body to detect disease – Shaastra

J&J’s move to exit talc globally need not raise any fresh concerns –

It’s not just a vaccine : mRNA also lends itself to therapeutics, but the technology’s flaws need to be fixed – Shaastra

OMG, it’s omega-3 : The sharpened pharmaceutical gaze on Omega 3 Fatty Acids is a game changer for the controversial nutrient that is hailed as a miracle pill as much as it is viewed with suspicion – Shaastra

Tests that take your breath away : A world striving for normalcy amid a pandemic turns into an early proving ground for exhaled breath testing – Shaastra

Extension of Covaxin’s shelf life has been mishandled

Squashing the super bug : A platform to combat antimicrobial resistance brings together diverse stakeholders from India and the world – Shaastra

Raising their game : Complex drugs going off-patent in the US means more hoops for Indian hoops for Indian pharma companies to jump through. But they are game for it. – Shaastra

Just Breathe Out : Medical advances have put the exhaled breath at the frontlines of efforts to diagnose killer diseases, and Indian scientists have joined the global quest -Shaastra 

To the point : The study of exhaled breath could aid the cause of precision medicine -Shaastra

Diagnosis at your doorstep : A number of Indian start-ups are harnessing cutting-edge technology to take screening and diagnosis closer to patients and the point-of-care – Shaastra

The Bold New Biotechpreneurs : A handful of Indian start-ups is venturing into the high-risk, high-attrition pursuit of new drugs, enabled by an emerging ecosystem – Shaastra

For now a middle ground in Indian healthcare –

India must close the tortuous discussions on medical device regulation –

Bottle of Lies: What ails India’s drug industry –

Lessons we must learn from the FDC fiasco –

Legalising compensation to patients of faulty medical devices: destination clear, but where is the road? –

The J&J hip implant case: On patient safety, India must up its game –

Indian healthcare providers need to get serious about infection control – Indian Express

Web drug platforms can only be as good as their partner-chemists on the ground – Indian Express

Untested drug combinations highlight the need to overhaul drug regulation – Indian Express

India’s drug pricing regime pulls off a logic-defying move – Quartz

Why India allows drugs banned elsewhere – Quartz

The ban on a popular diabetes drug shows poor side-effects monitoring – Indian Express

Changing the FDI policy will not improve the availability of essential drugs -Indian Express

The Ranbaxy scandal is more damaging to India’s image than to its prospects – Indian Express

Why the Supreme Court ruling on Glivec won’t bring down drug prices – Sunday ET

Dr Anji Reddy : The man who introduced India to the drug called innovation – Sunday ET



12 thoughts on “Author

  1. Hi Gauri,
    Nice to know about you. I may not be able to comment about the contents just now on the topic but i would be interested in knowing more about the health care industry as such and the scenario in mental issues in india and abroad.

    The title as meghna said is very appealing. Ills and Pills i am familiar with; i will look forward to the rest! writing about it I suppose is the thrill?

    Iam organising a magazine on psychology and neuroscience for the common man to be launched in a month or so. Any ideas and tips about this are welcome!
    All the best for your blog


  2. Hi Gauri,
    You might remember we had met during the inauguration of Bilcare Research Academy in Pune. You had also written an article on the availability of morphine for cancer patients, we are still working on that.
    Though there was high hope among people about the future of clinical research, the field has failed to do as well as expected for a variety of reasons. Good clinical research academies are shutting down (Bilcare Research Academy shut down last years, after a mere four years)
    I am now working in Symbiosis International University in the School of Biomedical Sciences. I still do a bit of writing and have recently published an article on morphine in cancer. It is available at:
    Do let me know if I can help you in any way.
    Dr. Ravindra Ghooi


    1. Hope you are well Dr Ghooi and thank you for connecting via this blog. It’s disappointing that cancer patients are still waging a battle to get their hands on painkilling opiods and I suppose there’s no other way than to keep up the pressure..Thank you for your article and do keep in touch


      1. Gauri,
        When Bilcare Research Academy was shut down, it left a number of people high and dry. Many people have not been paid their dues and have faced heavy loss. My own loss is over Rs. 10.75 lacs. I have gone to court against them. I would like to have your advice since you work in the area of pharmaceuticals and also know about finance. Is there any way that jounalists like you can help us?


  3. Hi,

    Your blog provides some wonderful insights on healthcare and is an informative read.
    I am working with a company called NeedStreet. It is an online healthcare platformed aimed to improve accessibility to healthcare through improved engagement between healthcare providers and patients. Given the skewed doctor-patient ratio, an online platform, coupled with mobile applications powered by NeedStreet, is the best bet to ensure quality care, wherever you may be located.
    Do take a look at Would love to hear your thoughts.


  4. Its interesting to read the articles. However, as a person working in clinical research I am yet to see any article from anyone regarding the myths that are currently spread in name of research by journals, by companies, NGO’s etc. The myths about cholesterol, statins etc are all there but do not reach the public. We generally hear about the deaths and disabilities in clinical research but the bigger issue lie in conducting it and then how the results get twisted before appearing in respected journals where doctors across the world lap it up. One question I will leave for you – have you seen any negative results of a clinical trials in your life. If you wish to see them read about trial No.329 done more than 10 years ago in Europe and US and read the same one published now again after a lot of effort and legal tussle.


  5. HI Gauri,

    Have been a follower of your work from 2001 i think! Glad to see your continued passion for the sector! Will continue to follow your work, goes without saying. Look forward.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s